From the Department of Pharmacy.
Children's Hospital of Michigan, Detroit Medical Center, Detroit, Michigan.
Pediatr Infect Dis J. 2020 May;39(5):419-420. doi: 10.1097/INF.0000000000002593.
The clinical use, safety and effectiveness of ceftolozane/tazobactam among 13 patients 3 months to 19 years of age infected with multidrug-resistant Pseudomonas aeruginosa are described. All but one patient achieved clinical cure after initial treatment. Adverse drug events attributed to treatment included transaminitis and neutropenia which occurred in 2 patients and resolved upon dose reduction.
描述了 13 名 3 个月至 19 岁患有多重耐药铜绿假单胞菌感染的患者使用头孢他洛滨/他唑巴坦的临床应用、安全性和有效性。除 1 名患者外，所有初始治疗后均获得临床治愈。与治疗相关的药物不良事件包括 2 例患者发生的转氨血症和中性粒细胞减少症，经剂量减少后得到解决。
